Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy
A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV)
A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy
A Phase I Trial of Olanzapine (ZYPREXA) For the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy
Clinicians’ Assessment Of Quality Of Life (QoL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction?
A Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting
A Phase II Study of Unresectable Pancreatic Cancer Treated with 5-FU and Leucovorin with Radiation Therapy
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI)
Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC)
The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer
Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer
A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)
A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis
Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease
A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC)
Improved Survival for Patients with Hormone-Refractory Prostate Cancer Receiving Estramustine-Based Antimicrotubule Therapy
A Phase III Trial of Vinblastine Versus Vinblastine plus Estramustine Phosphate for Metastatic Hormone-refractory Prostate Cancer (HRPC)
A Prospective Randomized Trial of Cyclophosphamide Versus Cyclophosphamide plus Adriamycin plus Methotrexate in Hormone Refractory Prostate Cancer
Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
A Phase III Study of Thoracic Irradiation With or Without Concomitant Cisplatin in Locoregional Unresectable Non-Small Cell Lung Cancer (NSCLC)
A Phase III Study of Thoracic Radiation With or Without Concurrent Cisplatin Chemotherapy in Locoregional Unresectable Non-Small Cell Carcinoma of the Lung
Phase II Trial of Daily Oral Etoposide in Patients with Surgically Unresectable Non Small Cell Lung Cancer
Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma
Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
A Phase III Multicenter Randomized Trial of DTIC, Cisplatin, BCNU and Tamoxifen Versus DTIC Alone in Patients with Metastatic Melanoma
Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
A Phase II Trial of Gefitinib (Iressa) in Patients With Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers
Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients
Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients
A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients With Localized, Unresectable Pancreatic Cancer
Phase I-II Study of Zidovudine (AZT) and Methotrexate (MTX) in Advanced Pancreatic Cancer and Hepatoma
A Multi-Centered Phase I/II Study of Cetuximab in Combination with Paclitaxel and Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer
A Phase III Study of Pemetrexed vs Docetaxel in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) who were Previously Treated with Chemotherapy
Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer
